Company news

Clene Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland

October 30, 2022

Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights

August 14, 2022

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

August 14, 2022

Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS

July 18, 2022

Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial

July 13, 2022

Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights

May 8, 2022

Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights

March 10, 2022

Clene Nanomedicine Provides Clinical Program Update

February 13, 2022

Clene Announces New Chief Financial Officer Morgan Brown

January 31, 2022

Clene Nanomedicine’s Facility Improvement Project Receives $1 Million Grant Award from the Maryland Department of Housing and Community Development (DHCD)

December 12, 2021

Clene Announces Completion of Patient Enrollment in the HEALEY ALS Platform Trial

November 14, 2021

Clene Reports Third Quarter 2021 Operating and Financial Highlights

November 8, 2021

Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial

November 1, 2021

Clene Announces Initiation of a Second FDA Expanded Access Program with CNM-Au8 for People Living with Amyotrophic Lateral Sclerosis

September 22, 2021

Clene Reports Second Quarter 2021 Operating and Financial Highlights

August 9, 2021

Clene Nanomedicine Appoints Dr. Vallerie McLaughlin to its Board of Directors

August 4, 2021

Clene Announces Plan to Expand its Manufacturing Capacity of CNM-Au8, Closing of Up to $30 Million Debt Facility, and Financing Agreements for $9.25 Million At-the-Market Private Placement

May 23, 2021

Clene Appoints David J. Matlin as Chairman of the Board

May 18, 2021

Clene Nanomedicine Receives Catalyst Award for Healthy Longevity from U.S. National Academy of Medicine to Accelerate the Development of CNM-Au8 for Neurodegenerative Diseases Associated with Aging

May 16, 2021

Clene Reports First Quarter 2021 Operating and Financial Highlights

May 10, 2021

Clene Reports Full Year 2020 Operating and Financial Highlights

March 28, 2021

Clene Nanomedicine Announces Achievement of 50% Enrollment in the Phase 3 HEALEY ALS Platform Trial

March 8, 2021

Clene Nanomedicine Awarded Michael J. Fox Foundation Grant to Accelerate the Development of CNM-Au8 as a Treatment for Parkinson’s Disease

February 28, 2021

Clene Nanomedicine Initiates Phase 2 Study of CNM-ZnAg for Patients with COVID-19

February 15, 2021

Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis

January 18, 2021

← Newer news releases

Decks

The 5 newest of 44 decks. Every deck is listed under its year.